Inflammation and B cell activation define a plasma proteome signature predicting tuberculosis in people with HIV
Open Access
- 8 October 2025
- journal article
- Published by American Society for Microbiology in mBio
- Vol. 16 (10) , e0158525
Abstract
Improved biomarkers for predicting progression to active tuberculosis (TB) are urgently needed, especially in people with HIV, who are at elevated risk. We used high-throughput plasma proteomics and machine learning to identify signatures associated with TB progression in this population. From the Swiss HIV Cohort Study, we analyzed plasma samples collected at least 6 months before TB diagnosis from 91 participants who later developed TB. We selected 293 controls matched for demographic and clinical parameters who remained TB-free to achieve a risk score specific to active TB. In total, 583 samples were analyzed, with 613–1,283 proteins quantified per sample. A random forest classifier predicted a significantly higher median probability of TB progression for cases (33%) than for controls (16%; P < 0.001). In this matched population, the score achieved an area under the receiver-operating characteristic curve of 0.77, an area under the precision-recall curve (AUPRC) of 0.60 (as compared to an expected AUPRC of 0.29), as well as a specificity of 87.3% and a sensitivity of 58.6% using the optimal threshold of 0.311. The plasma proteome of individuals who progressed to active TB showed a distinct shift toward systemic inflammation, B cell activation, and immunoglobulin production. Independent of progression to active TB, the proteome score correlated with broader indicators of immune suppression, including lower CD4 counts and unsuppressed HIV RNA. This suggests that integrating proteomic and clinical data could enhance the overall predictive power of the score. IMPORTANCE: We still lack reliable tools to predict who will develop tuberculosis (TB) among people with HIV. Moreover, the underlying biological events driving progression remain poorly understood. Our study reveals early immune changes that include unexpected alterations in B cell activation and antibody responses. These findings suggest that humoral immunity may play a more important role in TB pathogenesis than previously recognized and offer promising new directions for biomarker discovery and targeted prevention.Keywords
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (218408)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030_200407)
This publication has 30 references indexed in Scilit:
- From simple to complex: Protein‐based biomarker discovery in tuberculosisEuropean Journal of Immunology, 2023
- Mycobacterium tuberculosis disease associates with higher HIV-1-specific antibody responsesiScience, 2023
- A gas phase fractionation acquisition scheme integrating ion mobility for rapid diaPASEF library generationProteomics, 2023
- Plasma host protein biomarkers correlating with increasing Mycobacterium tuberculosis infection activity prior to tuberculosis diagnosis in people living with HIVEBioMedicine, 2021
- Progression from latent infection to active disease in dynamic tuberculosis transmission models: a systematic review of the validity of modelling assumptionsThe Lancet Infectious Diseases, 2018
- A Functional Role for Antibodies in TuberculosisCell, 2016
- A blood RNA signature for tuberculosis disease risk: a prospective cohort studyThe Lancet, 2016
- Serum protein S100A9, SOD3, and MMP9 as new diagnostic biomarkers for pulmonary tuberculosis by iTRAQ‐coupled two‐dimensional LC‐MS/MSProteomics, 2014
- Minimal, encapsulated proteomic-sample processing applied to copy-number estimation in eukaryotic cellsNature Methods, 2014
- Antibody-Mediated Immunity against Tuberculosis: Implications for Vaccine DevelopmentCell Host & Microbe, 2013